Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
The $5bn transaction was surely only made possible by shrinking valuations, but investors in both Glaxo and Tesaro have reasons to be unhappy.
Vantage has today published a detailed report into first-line lung cancer, discussing key upcoming trial readouts and regulatory decisions, and putting into context the…
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
A Yervoy combo of the Bristol-Myers Squibb drug has flunked Checkmate-451, a confirmatory study for treating small-cell lung cancer, and that means decision time for the…
Bayer tests what the market will bear for its newly approved therapy for cancers with NTRK mutations.